Anti-Human CD152 (CTLA-4) PE

Grouped product items
SizePrice Qty
25 tests
$100.00
100 tests
$240.00

Additional BNI3 Formats

Cat.No.FormatStarting From
14611-60PE$ 100.00
14611-20Purified$ 155.00
14611-80APC$ 115.00
14611-25SAFIRE Purified$ 220.00
Catalog Number : 14611-60

description

The BNI3 monoclonal antibody specifically reacts with human CD152, the Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4). CTLA-4 is expressed on activated CD28+ T cells, and binds the B7 family members B7-1 (CD80) and B7-2 (CD86). The structure of CTLA-4 is similar to the structure of CD28, but the two molecules seem to have opposite roles on the T lymphocytes. CTLA-4 inhibits the progression of T cell activation, while CD28 stimulates it. This result explains the stimulating role that the immobilization of BNI3 plays on the T lymphocytes proliferation induced by CD28.

Additional Information

Clone:
BNI3
Format:
PE
Applications:
FC
Reactivity:
Human
Isotype:
Mouse IgG2a, kappa
Research Interest:Adaptive Immunity
Cell Type:T Cells, T Regulatory Cells
Application:FC
Clone:BNI3
Preparation:
The product should be stored undiluted at 4°C and should be protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified utilizing affinity chromatography and unreacted dye was removed from the product.
Formulation:
Phosphate-buffered aqueous solution, ≤0.09% Sodium azide, may contain carrier protein/stabilizer, ph7.2.
References:

Barclay, A. N., Brown, M. H., Law, S. A. K. A., McKnight, A. J., Tomlinson, M. G., & van der Merwe, P. A. (1997). The leucocyte antigen factsbook. Academic Press.

Lindsten, T., Lee, K. P., Harris, E. S., Petryniak, B., Craighead, N., Reynolds, P. J., ... & Gray, G. S. (1993). Characterization of CTLA-4 structure and expression on human T cells. The Journal of Immunology151(7), 3489-3499.

Kuiper, H. M., Brouwer, M., Linsley, P. S., & Van Lier, R. A. (1995). Activated T cells can induce high levels of CTLA-4 expression on B cells. The Journal of Immunology155(4), 1776-1783.

© BioGems International, Inc. All rights reserved.